# A Pivotal Bioequivalence Study of DOXIL/CAELYX (Doxorubicin HCL) in Patients With Advanced or Refractory Solid Malignancies Including Patients With Ovarian Cancer

> **NCT01815294** · PHASE1 · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 54 (actual)

## Conditions studied

- Neoplasms
- Neoplasms, Ovarian
- Neoplasms, Breast
- Advanced or Refractory Solid Malignancies

## Interventions

- **DRUG:** DOXIL/CAELYX (doxorubicin) Treatment Sequence AB
- **DRUG:** DOXIL/CAELYX (doxorubicin) Treatment Sequence BA

## Key facts

- **NCT ID:** NCT01815294
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-05
- **Primary completion:** 2014-12
- **Final completion:** 2014-12
- **Target enrollment:** 54 (ACTUAL)
- **Last updated:** 2015-12-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01815294

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01815294, "A Pivotal Bioequivalence Study of DOXIL/CAELYX (Doxorubicin HCL) in Patients With Advanced or Refractory Solid Malignancies Including Patients With Ovarian Cancer". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT01815294. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*